DS
BBIO icon

David Shaw’s BridgeBio Pharma BBIO Stock Holding History

David Shaw’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$271M Buy
3,633,007
+1,087,521
+43% +$76.2M 0.13% 155
2026
Q1 		$189M Buy
2,545,486
+331,455
+15% +$24M 0.11% 207
2025
Q4 		$169M Sell
2,214,031
-38,731
-2% -$2.54M 0.09% 240
2025
Q3 		$117M Buy
2,252,762
+171,509
+8% +$8.36M 0.07% 349
2025
Q2 		$89.9M Buy
2,081,253
+1,998,104
+2,403% +$72.7M 0.06% 359
2025
Q1 		$2.87M Buy
+83,149
New +$2.8M ﹤0.01% 2332
2024
Q4 		– Sell
-80,746
Closed -$2.06M – 4415
2024
Q3 		$2.06M Sell
80,746
-143,382
-64% -$3.76M ﹤0.01% 2694
2024
Q2 		$5.68M Sell
224,128
-193,760
-46% -$5.3M 0.01% 1752
2024
Q1 		$12.9M Sell
417,888
-506,977
-55% -$17.2M 0.01% 1206
2023
Q4 		$37.3M Sell
924,865
-416,378
-31% -$12.5M 0.03% 592
2023
Q3 		$35.4M Sell
1,341,243
-291,743
-18% -$8.28M 0.04% 563
2023
Q2 		$28.1M Sell
1,632,986
-599,035
-27% -$9.01M 0.03% 683
2023
Q1 		$37M Sell
2,232,021
-468,803
-17% -$5.47M 0.04% 554
2022
Q4 		$20.6M Buy
2,700,824
+342,755
+15% +$3.28M 0.02% 897
2022
Q3 		$23.4M Sell
2,358,069
-90,390
-4% -$939K 0.03% 757
2022
Q2 		$22.2M Sell
2,448,459
-47,569
-2% -$398K 0.03% 798
2022
Q1 		$25.3M Buy
2,496,028
+1,209,939
+94% +$12.4M 0.02% 874
2021
Q4 		$21.5M Buy
1,286,089
+1,119,497
+672% +$47.4M 0.02% 1040
2021
Q3 		$7.81M Sell
166,592
-2,142
-1% -$115K 0.01% 1703
2021
Q2 		$10.3M Buy
168,734
+142,975
+555% +$8.17M 0.01% 1477
2021
Q1 		$1.59M Buy
+25,759
New +$1.69M ﹤0.01% 2777
2020
Q2 		– Sell
-112,589
Closed -$3.27M – 3978
2020
Q1 		$3.27M Buy
+112,589
New +$3.49M 0.01% 1787

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

David Shaw's BBIO Position: Q2 2026 in Review

David Shaw increased its BridgeBio Pharma (BBIO) stake by 43% in Q2 2026, buying an estimated $76.2M and bringing the position to 3,633,007 shares worth $271M. The position accounts for 0.13% of the portfolio, ranked #155.

David Shaw first reported a position in BBIO in Q1 2020 and has held it in 22 quarters since. 471 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • David Shaw held 3,633,007 shares of BridgeBio Pharma worth $271M as of Q2 2026.
  • David Shaw bought 1,087,521 BridgeBio Pharma shares in Q2 2026, an estimated $76.2M.
  • BridgeBio Pharma made up 0.13% of David Shaw's portfolio in Q2 2026, its #155 holding.
  • David Shaw first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 22 quarters since.
  • 471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.